The treatment of cancer stem cells with anti-miRNA-302 inhibitors upregulates lysine-specific histone demethylases and decreases DNA global demethylation, impairing HA-CD44-activated functions in cancer stem cells [93]. This evidence concerns the gene CD44 and cancer.